General Info
Host: | Rabbit |
Applications: | IHC/IF/WB |
Reactivity: | Human/Rat/Mouse/Goat |
Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: | Rabbit polyclonal antibody anti-B-cell lymphoma 3 protein (340-420 aa) is suitable for use in Immunohistochemistry, Immunofluorescence and Western Blot research applications. |
Clonality: | Polyclonal |
Conjugation: | Unconjugated |
Isotype: | IgG |
Formulation: | Liquid in PBS containing 50% Glycerol and 0.02% Sodium Azide. |
Purification: | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
Concentration: | 1 mg/mL |
Dilution Range: | WB 1:500-2000ELISA 1:5000-20000IF 1:50-200 |
Storage Instruction: | Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Information
Gene Symbol: | BCL3 |
Gene ID: | 602 |
Uniprot ID: | BCL3_HUMAN |
Immunogen Region: | 340-420 aa |
Specificity: | BCL3 Polyclonal Antibody detects endogenous levels of protein. |
Immunogen: | Synthesized peptide derived from the human protein at the amino acid range 340-420 |
Description
Function | Contributes to the regulation of transcriptional activation of NF-kappa-B target genes. In the cytoplasm, inhibits the nuclear translocation of the NF-kappa-B p50 subunit. In the nucleus, acts as transcriptional activator that promotes transcription of NF-kappa-B target genes. Contributes to the regulation of cell proliferation. |
Protein Name | B-Cell Lymphoma 3 ProteinBcl-3Proto-Oncogene Bcl3 |
Cellular Localisation | NucleusCytoplasmPerinuclear RegionUbiquitination Via 'Lys-63'-Linked Ubiquitin Chains Is Required For Nuclear Accumulation |
Alternative Antibody Names | Anti-B-Cell Lymphoma 3 Protein antibodyAnti-Bcl-3 antibodyAnti-Proto-Oncogene Bcl3 antibodyAnti-BCL3 antibodyAnti-BCL4 antibodyAnti-D19S37 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance